BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 14747572)

  • 1. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
    J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.
    Argyris EG; Pomerantz RJ
    Trends Microbiol; 2004 Apr; 12(4):145-8. PubMed ID: 15116720
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
    Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between HIV-1 Gag and APOBEC3G.
    Cen S; Guo F; Niu M; Saadatmand J; Deflassieux J; Kleiman L
    J Biol Chem; 2004 Aug; 279(32):33177-84. PubMed ID: 15159405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G.
    Takeuchi H; Kao S; Miyagi E; Khan MA; Buckler-White A; Plishka R; Strebel K
    J Biol Chem; 2005 Jan; 280(1):375-82. PubMed ID: 15528183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
    Yang B; Chen K; Zhang C; Huang S; Zhang H
    J Biol Chem; 2007 Apr; 282(16):11667-75. PubMed ID: 17272283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
    Kao S; Miyagi E; Khan MA; Takeuchi H; Opi S; Goila-Gaur R; Strebel K
    Retrovirology; 2004 Sep; 1():27. PubMed ID: 15373943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Conticello SG; Harris RS; Neuberger MS
    Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further investigation of simian immunodeficiency virus Vif function in human cells.
    Gaddis NC; Sheehy AM; Ahmad KM; Swanson CM; Bishop KN; Beer BE; Marx PA; Gao F; Bibollet-Ruche F; Hahn BH; Malim MH
    J Virol; 2004 Nov; 78(21):12041-6. PubMed ID: 15479843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.